Scholar Rock Holding annual revenue
2018
2019
2020
2021
2022
2023
2024
2025
Scholar Rock Holding reported $0 in revenue for fiscal 2025.
View full Scholar Rock Holding company overview| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $0 | $0 | — |
| 2024 | 2024-12-31 | $0 | $0 | — |
| 2023 | 2023-12-31 | $0 | −$33.2M | −100.00% |
| 2022 | 2022-12-31 | $33.2M | $14.4M | +76.41% |
| 2021 | 2021-12-31 | $18.8M | $3.4M | +22.16% |
| 2020 | 2020-12-31 | $15.4M | −$5.1M | −24.83% |
| 2019 | 2019-12-31 | $20.5M | $20.5M | — |
| 2018 | 2018-12-31 | $0 | — | — |
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0 | $0 | — |
| Q1 2026 | 2026-03-31 | $0 | — | — |
| Q4 2025 | 2025-12-31 | $0 | — | — |
| Q3 2025 | 2025-09-30 | $0 | — | — |
| Q2 2025 | 2025-06-30 | $0 | — | — |
| Q4 2022 | 2022-12-31 | $0 | −$4.0M | −100.00% |
| Q3 2022 | 2022-09-30 | $0 | −$5.5M | −100.00% |
| Q2 2022 | 2022-06-30 | $0 | −$4.6M | −100.00% |
| Q1 2022 | 2022-03-31 | $33.2M | $28.5M | +605.03% |
| Q4 2021 | 2021-12-31 | $4.0M | $613,000 | +17.84% |
| Q3 2021 | 2021-09-30 | $5.5M | $2.4M | +79.91% |
| Q2 2021 | 2021-06-30 | $4.6M | $695,000 | +17.82% |
| Q1 2021 | 2021-03-31 | $4.7M | −$322,000 | −6.40% |
| Q4 2020 | 2020-12-31 | $3.4M | −$4.1M | −54.63% |
| Q3 2020 | 2020-09-30 | $3.0M | −$1.7M | −36.38% |
| Q2 2020 | 2020-06-30 | $3.9M | −$1.1M | −22.60% |
| Q1 2020 | 2020-03-31 | $5.0M | $1.9M | +61.94% |
| Q4 2019 | 2019-12-31 | $7.6M | — | — |
| Q3 2019 | 2019-09-30 | $4.8M | $4.8M | — |
| Q2 2019 | 2019-06-30 | $5.0M | $5.0M | — |
| Q1 2019 | 2019-03-31 | $3.1M | — | — |
| Q3 2018 | 2018-09-30 | $0 | $0 | — |
| Q2 2018 | 2018-06-30 | $0 | $0 | — |
| Q3 2017 | 2017-09-30 | $0 | — | — |
| Q2 2017 | 2017-06-30 | $0 | — | — |
Scholar Rock Holding's latest reported quarter, Q2 2026, generated $0 in revenue.
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Scholar Rock Holding source filings ↗Scholar Rock ($SRRK) received FDA approval for ISEMBYLD, its apitegromab treatment for spinal muscular atrophy, in patients aged two and older receiving SMN2-targeted therapy. The company plans to begin shipping the medicine within days. Th ...